Company Profile
Neurocrine Biosciences Stock Price, News & Analysis
- Ticker:
- NBIX
- Exchange:
- NASDAQ
- Sector:
- Biotechnology
- Location:
- San Diego, California
Stock performance
174.10 USD (-1.70%)
Close
Last updated: July 13, 2026 at 00:00
17.81B USD
Market cap
Why the stock is moving
NBIX is trading with a steady catalyst profile while investors wait for the next headline that changes the story.
Company overview
Business overview
Neurocrine Biosciences is a neuroscience-focused biopharmaceutical company with a commercial base and a pipeline tied to movement disorders and other specialty indications. Investors watch how the company extends its franchise beyond the lead commercial asset.
Geographic Base and Sector Classification
Headquartered in San Diego, California and listed on NASDAQ, Neurocrine is followed within the neuroscience universe for its commercial base and specialty-disease exposure.
Business Model Characteristics
Neurocrine combines product commercialization with pipeline development, so the market focuses on launch execution, label expansion, and the next wave of neuroscience programs.
Position Within the Biotechnology Landscape
Compared with smaller biotech peers, Neurocrine sits closer to the commercial-neuroscience end of the landscape, where execution and pipeline renewal both matter.
Future catalysts
Recent news
The five most recent related feed items are shown below in reverse chronological order.
- 01
Zimmer Biomet Names Chintan Desai President of Asia Pacific Region
ZBH · Source: Zimmer Biomet
- 02
Zimmer Biomet Announces Webcast and Conference Call of Second Quarter 2026 Financial Results
ZBH · Source: Zimmer Biomet
- 03
U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma
BMY · Source: BMYBristol-Myers Squibb Company
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Neurocrine Biosciences (NBIX)?
Neurocrine Biosciences (NBIX) most recently closed at 174.10 USD, a -1.70% move versus the previous session.
What is the market cap of Neurocrine Biosciences (NBIX)?
Neurocrine Biosciences currently has a market capitalization of 17.81B USD on BioPharmSignal.
What does Neurocrine Biosciences do?
Neurocrine Biosciences is a neuroscience-focused biopharmaceutical company with a commercial base and a pipeline tied to movement disorders and other specialty indications. Investors watch how the company extends its franchise beyond the lead commercial asset.
On which exchange is NBIX stock listed?
Neurocrine Biosciences (NBIX) is associated with NASDAQ, San Diego, California, Biotechnology.
What is Neurocrine?
Neurocrine Biosciences is a neuroscience-focused biopharmaceutical company with a commercial base and a pipeline tied to movement disorders and other specialty indications.
Which conditions is Neurocrine Biosciences targeting with Neurocrine?
Neurocrine Biosciences is associated with neuroscience based on its company overview and current catalyst commentary.
What is Biosciences?
Neurocrine Biosciences is a neuroscience-focused biopharmaceutical company with a commercial base and a pipeline tied to movement disorders and other specialty indications.
What is Investors?
Investors watch how the company extends its franchise beyond the lead commercial asset.